Trial Profile
A SINGLE SITE EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CONCURRENT CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH ADVANCED LOCOREGIONAL SQUAMOUS CELL CARCINOMAS OF THE HEAD AND NECK.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2021
Price :
$35
*
At a glance
- Drugs Amifostine (Primary) ; Carboplatin; Paclitaxel
- Indications Head and neck cancer; Pharyngeal neoplasms; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms GCC 0202
- 06 Feb 2017 New trial record